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Abstract
Axon degeneration occurs in all neurodegenerative diseases, but the molecular pathways regulating axon destruction
during neurodegeneration are poorly understood. Sterile Alpha and TIR Motif Containing 1 (Sarm1) is an essential
component of the prodegenerative pathway driving axon degeneration after axotomy and represents an appealing target for
therapeutic intervention in neurological conditions involving axon loss. Amyotrophic lateral sclerosis (ALS) is characterized
by rapid, progressive motor neuron degeneration and muscle atrophy, causing paralysis and death. Patient tissue and
animal models of ALS show destruction of upper and lower motor neuron cell bodies and loss of their associated axons.
Here, we investigate whether loss of Sarm1 can mitigate motor neuron degeneration in the SOD1G93A mouse model of ALS.
We found no change in survival, behavioral, electrophysiogical or histopathological outcomes in SOD1G93A mice null for
Sarm1. Blocking Sarm1-mediated axon destruction alone is therefore not sufficient to suppress SOD1G93A-induced
neurodegeneration. Our data suggest the molecular pathways driving axon loss in ALS may be Sarm1-independent or
involve genetic pathways that act in a redundant fashion with Sarm1.
Introduction
Axon degeneration is a hallmark of neurodegenerative disease
(1), but we lack a detailed understanding of the signaling
pathways that promote this destructive process in any major
disorder. Significant progress has however been made in the
characterization of molecules that regulate axon destruction
after axotomy, termed Wallerian degeneration (2). Initial
molecular insights into Wallerian degeneration came from the
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spontaneous mouse mutant Wallerian degeneration slow (WldS)
(3). Remarkably, while severed axons of wild-type mice typically
undergo destruction and clearance within days, WldS mutant
axons remain intact for weeks after lesion. This neuroprotective
effect of WldS mapped to a genome rearrangement producing a
neomorphic fusion protein (4), with the key protective activity
determined to be that of Nicotinamide adenine dinucleotide
(NAD+) biosynthetic enzyme nicotinamide mononucleotide
adenylyltransferase 1 (Nmnat1) (5). The WldS mutant radically
changed our views on axon biology—demonstrating that axon
destruction could be regulated and that under some conditions
axons could suvive for long periods without a cell body.
Is there an endogenous pathway that actively drives
axon auto-destruction? An unbiased forward-genetic screen
in Drosophila for mutants that phenocopied WldS led to the
discovery of the Sterile Alpha and TIR Motif Containing 1
(dSarm/Sarm1), a founding member of the axon death signaling
pathway engaged after axotomy (6). In dsarm null mutant
backgrounds, distal severed axons survived for weeks post-
axotomy, an effect that was found to be conserved after sciatic
nerve lesion in mice (6,7). Moreso, as the Sarm1 protein is highly
conserved between humans and rodents (Human accession
number: Q6SZW1-1, Mouse accession number Q6PDS3-1; 94%
identity, 99% coverage), functional conservation is likely. At
least two additional genes have subsequently been identified
as similarly potent regulators of axon degeneration: the E3
ubiquitin ligase Phr1/Highwire (8–10) and the bric-a`-brac,
tramtrack, broad complex (BTB)/BTB and C-terminal Kelch
(BACK) domain containing gene Axundead (11).
Given that each of these molecules are essential for efficient
axon degeneration after axotomy, they represent exciting new
potential targets for therapeutic blockade of axon loss in disease.
The mitigating activity of WldS has previously been assessed
in models of toxin-induced neuropathies (12,13), gracile axonal
dystrophy (14), glaucoma (15,16), Parkinson’s disease (17,18) and
motor neuron diseases including amyotrophic lateral sclero-
sis (ALS) (19–21) and met with some success, suggesting that
treating the axon is a viable approach. The discovery of Sarm1
and other axon death signaling molecules warrants a reassess-
ment of the role of axon degeneration pathways in neurode-
generative diseases. Indeed, a recent study has demonstrated
that the deletion of Sarm1 is in fact significantly more protec-
tive than WldS expression in an Nmnat2 depletion model of
neurodegeneration (22).
ALS exists in idiopathic and less common familial forms
and is characterized by progressive paralysis, a consequence
of profound destruction of motor neurons and their axons
(23). Notably, Single nucleotide polymorphisms associated
with Sarm1 have been detected in genome-wide association
study of sporadic ALS patients, suggesting the gene may
even play a direct role in ALS pathogenesis (24). In this
study we tested whether elimination of Sarm1 was sufficient
to block axon destruction by the human SOD1G93A mutant
molecule in the transgenic mouse model of ALS. We found
that loss of Sarm1 was sufficient to block Wallerian degen-
eration in 1-year-old control mice, and at early stages in
transgenic mice expressing mutant SOD1. However, elimi-
nation of Sarm1 was not sufficient to mitigate behavioral,
morphological or electrophysiological deficits observed in
motor neurons in the ALS mouse. Our findings indicate the
molecular pathways driving axon loss in the SODG93A model
may be Sarm1-independent or that in the context of disease
Sarm1 acts in a redundant fashion with other pro-degenerative
signaling pathways.
Results
Degeneration of severed axons in aged mice
is ameliorated by loss of Sarm1
The paralytic symptoms of ALS result from the progressive
degeneration of upper and lowermotor neurons and their axons,
with typical disease onset in adulthood and risk increasing with
age.We have previously demonstrated that when severed in vivo,
peripheral nerve axons of young Sarm1 knock out (Sarm1KO)
mice are robustly protected against Wallerian degeneration (6).
For Sarm1 to be a viable target for treatment of ALS or other
late-onset neurodegenerative diseases this mechanism of pro-
grammed axon destruction must be maintained in aged neu-
rons. To test this, we lesioned the sciatic nerves of 1-year-old
Sarm1KO mice and inspected the morphology of myelinated
motor and sensory axons in the distal, severed nerve portion
14 days post-lesion (Fig. 1A). Consistent with young animals the
nerves of aged wild-type control mice were in a highly degen-
erate state, with normal myelinated axons absent. In Sarm1KO
mice, however, a substantial proportion of axons retained nor-
mal morphology, included being enclosed by an intact myelin
sheath. Protection at this mature adult stage demonstrates that,
rather than being a mechanism retained from development in
young adult neurons, Sarm1-mediated axon destruction is an
intrinsic characteristic of post-developmental neurons that may
contribute to neurodegeneration and injury.
Mutant SOD1G93A does not impede protection against
Wallerian degeneration in Sarm1 null nerves
SOD1G93A transgenic mice express high levels of mutant SOD1
protein throughout their nervous system (25). It was important
to confirm that excessive levels of this protein did not interfere
with normal Sarm1-mediated Wallerian degeneration. Sciatic
nerve axotomy experiments were conducted in young SOD1G93A
transgenic mice that were Sarm1 heterozygous (Sarm1Het),
where axotomy phenotype is as wild type or null for Sarm1
(Fig. 1B). At 14 days post-lesion myelinated axons of Sarm1Het
mice expressing SOD1G93A underwent axon degeneration
comparable to that observed in control Sarm1Het and aged
Sarm1WT (Fig. 1A) animals. Mutant SOD1 transgenic axons
in Sarm1KO mice were comparably protected from Wallerian
degeneration to those of Sarm1KO control mice, confirming that
the human SOD1G93A transgene does not impede protection of
severed axons.
Blocking Sarm1-mediated axon destruction does not
alter the acquisition of motor defects in the SOD1G93A
transgenic mouse
Having confirmed Sarm1-mediated Wallerian degeneration
occurs normally in the SOD1G93A transgenic mouse, we next
tested if this mechanism contributes to the chronic neurode-
generative and subsequent paralytic phenotype developed by
these animals (Fig. S1). We generated a colony of SOD1G93A
transgenicmice either heterozygous for Sarm1,whereWallerian
degeneration occurs normally, or homozygous null for Sarm1
where distal severed axons are preserved (Fig. 1B). Mice were
blindly scored daily for onset of tremor at early stages of disease
and onset of paralysis of the hind limbs at later stages (Fig. 2A,B).
There was no significant difference in the presentation of
either of these symptoms between Sarm1 heterozygous or
null SOD1G93A transgenic mice (Sarm1Het SOD1G93A, n = 37;
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Figure 1. Sarm1-mediated axon destruction can be suppressed in agedmice and is not altered by transgenic expression ofmutant SOD1. (A) Representativemicrographs
showing toluidine blue-stained intact or axotomized sciatic nerves of 1-year-old wild-type Sarm1KO mice. Morphologically intact axons were widespread in the distal
sciatic nerve 14-day post-lesion in Sarm1KO mice. (B) Representative images of intact or axotomized sciatic nerve of 5-week-old control and SOD1G93A transgenic mice
14 days post-axotomy, showing preservation of axons in SarmKO mice. Scale bar = 20 μm.
Sarm1KO SOD1G93A, n = 44. Tremor onset: Sarm1Het SOD1G93A,
78.0; Sarm1KO SOD1G93A, 79.5. Log-Rank (Mantel–Cox test):
χ2 = 0.8999, df = 1, P-value = 0.3428. Hind limb paralysis
onset: Sarm1Het SOD1G93A, 165.0; Sarm1KO SOD1G93A, 166.0. Log-
Rank (Mantel–Cox test): χ2 = 0.1047, df = 1, P-value = 0.7462).
Furthermore, no difference was detected in lifespan between
SOD1G93A transgenic mice heterozygous or null for Sarm1
(Fig. 2C) (Sarm1Het SOD1G93A, n = 37; Sarm1KO SOD1G93A, n = 44;
Sarm1Het SOD1G93A, 167.0; Sarm1KO SOD1G93A, 167.0. Log-Rank
(Mantel–Cox test): χ2 = 0.005961, df = 1, P-value = 0.9385). We
next assayed for potential rescue of sensorimotor function
in the Sarm1KO background more quantitatively by using
rotarod (Fig. 2D) and grip strength testing (Fig. S2). Though
SOD1G93A expression resulted in progressive and significant
deline in motor performance post-hoc tests did not detect
any significant changes in sensorimotor defects associated
with SOD1G93A in the Sarm1 null background compared to
sibling heterozygous controls in either rotarod (SOD1G93A groups,
n = 20; control groups, n = 15; FInteraction (34 864) = 11.75,
P-value < 0.0001; FTimepoint (17 864) = 35.34, P-value < 0.0001;
FGenotype (2864) = 559.2, P-value < 0.0001; Bonferroni post-hoc
analysis detected no significant differences between SOD1G93A
transgenic groups) or grip strength test (Fig. S2). These data
indicate that elimination of Sarm1 is not sufficient to delay
the onset or progression of the chronic motor deficits in the
SOD1G93A mice.
ALS-associated deficits in neuromuscular
electrophysiological function are not protected by loss
of Sarm1
Although removed from neuronal circuits through loss of their
cell body and dendrites, severed axons protected fromWallerian
degeneration are able to maintain electrophysiological function
and evoke action potentials in response to artificial stimulation
(4,11). It was thus feasible that despite not ameliorating the over-
all ALS-like phenotypes of SOD1G93A mouse, Sarm1 null motor
neuronsmay preserve their total number and size of their motor
units and maintain their ability to conduct action potentials
relative to SOD1G93A mice expressing Sarm1.
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Figure 2. Sarm1 does not contribute to onset, survival or sensorimotor performance deficits in SOD1G93A mice. Percentage of transgenic colony free of (A) hind limb
tremor and (B) hind limb paralysis. (C) Kaplan–Meyer plot showing survival of transgenic cohorts (A–C: Sarm1Het SOD1G93A, n= 37; Sarm1KO SOD1G93A, n= 44; Sarm1Het
control, n = 31; Sarm1KO control, n = 27; Sarm1Het SOD1G93A vs Sarm1KO SOD1G93A; Log-Rank test, P-value > 0.05). (D) Fall latency of male transgenic mice on 4–40 rpm
accelerating rotarod task for assessment of sensorimotor function (SOD1G93A groups, n = 20; control groups, n = 15; two-way ANOVA with Bonferonni post-hoc test).
To explore this possibility we used motor unit number
estimation (MUNE) (26) to quantify several features of electro-
physiological functional decline in the gastrocnemius muscle of
our experimental cohorts (Fig. 3,S3). MUNE gives an estimation
of the number of intact motor units present in a stimulated
muscle, providing a robust read-out of neuromuscular electro-
physiological decline in both ALS patients and rodent models
(27,28). Assessment of adult control mice wild-type, heterozy-
gous or homozygous null for Sarm1 detected no significant
difference in the MUNE score. Therefore, loss of Sarm1 does
not affect normal neuromuscular electrophysiological function
as measured by MUNE (Fig. 3A). However, in p120–130 mice
expressing the SOD1G93A transgene we found a significant
reduction in MUNE score (n = 4–14; two-way analysis of
variance (ANOVA): FSarm1Genotype (2,37) = 1.692, P-value = 0.1981;
FSOD1Genotype (1,37) = 301.4, P-value < 0.0001; Bonferonni post-
hoc test, ***P-value < 0.001). Loss of Sarm1 did not have a
significant effect at this point nor at the early symptomatic
p80–90 stage (Fig. S3). As MUNE score declines in ALS, a compen-
satory increase in motor unit size is seen with in both patients
(28) and rodent models (27). Expression of SOD1G93A indeed
resulted in an increased motor unit size in controls, which was
also present in all Sarm1 genotypes at p120–130 when compared
to their littermate controls not expressing the SOD1G93A
transgene, although this trend was not statistically significant
in the Sarm1KO cohort (Fig. 3B). Post-hoc analysis between
SOD1G93A transgenic mice of differing Sarm1 genotypes revealed
no significant difference between motor unit size in Sarm1
genotypes at p120–130 (n = 4–14; two-way ANOVA: FSarm1Genotype
(2,37) = 1.148, P-value = 0.3283; FSOD1Genotype (1,37) = 43.48,
P-value < 0.0001; Bonferonni post-hoc test, **P-value < 0.01)
or the earlier p80–90 time point (Fig. S3). Changes in motor unit
size are a result of plasticity at the neuromuscular junction (NMJ)
synapse. These data reveal that loss of Sarm1 does not play a
biologically significant role in protecting motor unit size from
increases in the context of the SODG93A model, arguing that loss
of Sarm1 does not affect major aspects of synaptic plasticity.
Finally, we assessed compoundmotor action potential (CMAP), a
measure of total activity from synchronized action potentials
reaching the muscle following simultaneous stimulation of
multiple axons within a bundle. As with MUNE, total CMAP
within the gastrocnemius was significantly reduced in mice
expressing SOD1G93A. In control mice, the total CMAP was not
altered in Sarm1KO animals compared to Sarm1Het or Sarm1WT,
indicating loss of Sarm1 does not alter CMAP properties;
however, the absence of Sarm1 did not ameliorate the deficits
in CMAP observed in the presence of SODG93A (Fig. 3C; n = 4–14;
two-way ANOVA: FSarm1Genotype (2,37) = 3.152, P-value = 0.0545;
FSOD1Genotype (1,37) = 260.5, P-value < 0.0001; Bonferonni post-
hoc test, ***P-value < 0.001). Together, these data reveal that
overall neuromuscular properties are relatively normal in
Sarm1KO animals,and that blockade of Sarm1 signaling alone is
not sufficient to alter the decline in electrophysiological function
of motor neurons in SOD1G93A mice.
Loss of Sarm1 does not preserve motor neuron axons
or terminals in SOD1G93A transgenic mice
Neurodegeneration occurs throughout motor neurons of
SOD1G93A transgenic mice, with the cell body, axons and
NMJs all being lost during the progression of pathology (29).
Interestingly, these neurodegenerative mechanisms appear to
be somewhat compartmentalized: suppression of apoptosis in
SOD1 transgenic mice preserves spinal cord motor neuron cell
bodies but does not rescue motor axons nor disease progression
(30). Although we found that loss of Sarm1 failed to ameliorate
any of the behavioral and physiological phenotypes of SOD1G93A
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Figure 3. Deficits in neuromuscular electrophysiological function associated
with SOD1G93A expression are not ameliorated in mice lacking Sarm1. Neuro-
muscular electrophysiological functionwas tested in SOD1G93A and controlmice
of Sarm1WT (black), Sarm1Het (blue) or Sarm1KO (red) genotype. Assessing the
gastrocnemiusmuscle of p120–130mice for (A) MUNE, (B) motor unit size and (C)
CMAP failed to show any significant difference in phenotype between SOD1G93A
transgenic groups (mean ± SEM, n = 4–14; two-way ANOVA with Bonferonni
post-hoc test; ns = non-significant; **P-value < 0.01; ***P-value < 0.001).
transgenic mice, it was conceivable that motor axons might
remain morphologically intact with pathology being driven by
degeneration of cell bodies or dendrites rendering the cells
inactive. To determine whether axons were preserved we first
quantified the number of myelinated motor axons with normal
morphology present within the L5 ventral nerve root mutant
SOD1G93A transgenic cohorts at early, mid and end stages of
pathology. When compared to transgenic mice carrying Sarm1,
we found that no significant differences in number of healthy
axons were seen in Sarm1 null mice at any stage in pathology
(Fig. 4A–C: p90 SOD1G93A Sarm1WT, n = 4; SOD1G93A Sarm1Het,
n = 4; SOD1G93A Sarm1KO, n = 3. One-way ANOVA: FSarm1Genotype
(2,8) = 1.133, P-value = 0.3688; p120–130 SOD1G93A Sarm1KO,
n = 4; SOD1G93A Sarm1Het, n = 11; SOD1G93A Sarm1KO, n = 7.
One-way ANOVA: FSarm1Genotype (2,19) = 2.272, P-value = 0.1304;
end-stage SOD1G93A Sarm1Het, n = 3; SOD1G93A Sarm1KO, n = 6.
Unpaired two-tailed t test: t = 1.974, df = 7, P-value = 0.089).
Large caliber Aα motor axons typically degenerate earlier
than smaller fibers in the SOD1G93A mouse, suggesting that
some pools of fibers are inherently more vulnerable to the
neurodegenerative insults associated with ALS. We therefore
assessed the diameter of remaining healthy axons within the
ventral nerve root, however found the distribution of fiber
caliber to be consistent between SOD1G93A transgenic cohorts
regardless of Sarm1 genotype (Fig. 4A′–C′: p90 two-way ANOVA:
FSarm1Genotype (2, 160) = 0.0004591, P-value = 0.9995; Bonferonni
post-hoc test, *P-value < 0.05, **P-value < 0.01; p120 two-way
ANOVA: FSarm1Genotype (2, 380) = 0.0001358, P-value = 0.9999;
Bonferonni post-hoc test, *P-value < 0.05, **P-value < 0.01;
endpoint two-way ANOVA: FSarm1Genotype (1, 140) = 0.0008991,
P-value = 0.9761; Bonferonni post-hoc test, *P-value < 0.05,
**P-value < 0.01).
In addition to driving the programmeddegradation of severed
axons, Sarm1 also contributes to the destruction of synapses in
response to injury. We have previously found that following
transection of Sarm1 null mouse peripheral nerves, NMJs corre-
sponding to severed motor axons maintain their innervation of
target muscles for several days post-injury (6). As widespread
loss of NMJs occurs in ALS, we assessed whether Sarm1 is
required for the degeneration of the distal axon andNMJ synapse
of SOD1G93A mice. Initial innervation patterns in gastrocnemius
muscles in presymptomatic Sarm1KO mice expressing SOD1G93A
were comparable to Sarm1Het and Sarm1WT SOD1G93A transgenic
animals. Quantification of NMJs at mid to late time points
demonstrated progressive loss of intact terminals in all SOD1G93A
transgenic cohorts; however, no significant differences were
detected between Sarm1Het or Sarm1KO mice at any time point
assessed (Fig. 5,S4; p120, n = 3–5; two-way ANOVA: FSarm1Genotype
(2,16) = 1.897, P-value = 0.1822; FSOD1Genotype (1,16) = 68,
P-value < 0.0001). Taken together, our results suggests elimina-
tion of Sarm1 signaling is not sufficient to block the progressive
destruction of motor neuron axons or their synaptic junctions
driven by overexpression of mutant SOD1.
Discussion
The promotion of regulated axon destruction by Sarm1 presents
an appealing target for the treatment of neurodegenerative
diseases and injury where pronounced axon degeneration
occurs. In the present study we found that genetic suppression
of Wallerian-like axon destruction by deletion of Sarm1 neither
attenuates axon degeneration nor alters hallmark features of
disease progression in the SOD1G93A transgenic mouse model
of ALS. Our findings are in line with previous studies of the
role of Wallerian-like degeneration in models of motor neuron
diseases. Expression of the potent suppressor of Wallerian
degeneration Wlds in models of motor neuron degeneration
previously yielded varied results, with only modest protection
having been reported in SOD1G93A transgenicmice (20). Similarly,
the degenerative phenotypes in SOD1G37R or SOD1G85R transgenic
mouse models were not changed by the presence of WldS
(21). However, in the pmn mouse model of progressive motor
neuronopathy, which entails axon degeneration followed by
motor neuron death, WldS significantly suppressed axon loss,
rescued motor neuron death and extended animal lifespan (19).
These observations validate the notion that treating the axon
in some contexts can save neurons, but our data suggest that
blocking axon degeneration alone with Sarm1 is not sufficient
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Figure 4. Progressive loss of myelinated motor axons is not ameliorated by loss of Sarm1. Total number of myelinated axons in the L5 ventral nerve root of SOD1G93A
transgenic mice wild type, heterozygous-null or homozygous-null for Sarm1 at (A) p80–90, (B) p120–130 and (C) end stage (n = 3–11, mean ± SEM; A and B, one-
way ANOVA; C, Student t test). Frequency distribution of axon diameters at (A′) p90, (B′) p120 and (C′) endpoint expressed as percentage of total axons measured
(mean ± SEM, two-way ANOVA with Bonferonni post-hoc test, *P-value < 0.05, **P-value < 0.01). (D) Representative images of L5 ventral nerve root myelinated axons
at p120 in SOD1G93A mice wild-type, heterozygous-null or homozygous-null for Sarm1 with comparison images from littermate controls not expressing SOD1G93A
(scale bar = 20 μm).
to ameliorate SODG93A mutant henotypes. Perhaps the severity
and rapid time scale of pathology in SOD1 transgenic rodent
models pose a limitation in these studies. Although this model
recapitulates the cardinal pathologies of ALS, the potency of
high-level overexpression of SODG93A might potentially mask
any modifying effects of Sarm1 on disease progression.
The contribution ofWallerian-like axon degeneration in ALS-
associated phenotypes has also been tested in invertebrate
models. Loss of Tir-1, the Caenorhabditis elegans homolog of
Sarm1, delays paralysis induced by expression of mutant of
FUS RNA Binding Protein or TAR DNA-Binding Protein 43 (TDP-
43) in worms (31). The authors suggest expression of the ALS
mutant genes leads to secretion of currently unknownmolecules
from neurons, activating Tir-1 and the downstream MAP-kinase
cascade triggering both an innate immune response and neuron
degeneration, though an effect upon neuronal morphology was
not reported. In contrast, neither the expression ofWldS nor loss
of dSarm or Phr1/Highwire was found to delay morphologically
defined degeneration of NMJ in Drosophila expressing mutant
TDP-43 in motor neurons (32). Taken together these in vivo
studies in rodent and invertebrate models of ALS argue the
molecular pathways promoting Wallerian degeneration, may
not be the primary drivers of axon loss or, at a minimum, are
functionally redundant with other prodegenerative signaling
pathways.
We have found Sarm1 to robustly drive Wallerian axon
destruction at both juvenile (Fig. 1B,(6)) and mature adult stages
(Fig. 1A), demonstrating that the genes role in this degenerative
process is neither restricted to development nor substantially
impeded by age. Why, however, inhibition of Sarm1 mediated
axon degeneration has such a profound effect on Wallerian
degeneration even in neurons at advanced ages but fails to
ameliorate ALS-associated neurodegeneration is unclear. Our
study demonstrates that in Sarm1 null animals expressing
mutant SOD1, Wallerian degeneration of the distal injured axon
is impeded (Fig. 1B) but not ALS-associated axonal degeneration
(Fig. 4D).Whether any of thesemodelsmeaningfully recapitulate
the molecular mechanisms driving axon loss in patients
remains unclear; but if so, our findings suggest the underlying
mechanisms may be molecularly distinct.
The role of mitochondria in different forms of neurode-
generation may also be a factor, with evidence suggesting
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Figure 5. Sarm1 does not contribute to NMJ denervation in SOD1G93A transgenic mice. (A) Representative images of immunofluorescent staining of NMJs in the
gastrocnemius muscle at p120–130. (Green = synaptophysin and beta-III-tubulin co-stain, Red = alpha-bungarotoxin, scale bar = 50 μm) (B) Percentage of innervated
NMJs in the gastrocnemius muscles of transgenic cohorts at p120–130 (mean ± SEM, n = 3–5, two-way ANOVA with Bonferonni post-hoc test, *P-value < 0.05,
**P-value < 0.01, ***P-value < 0.001).
mitochondrial biology contributes to the protective activity
of Sarm1 and WldS. Both proteins localize to mitochondria
(33–35), with Sarm1 robustly protecting cultured neurons from
the downstream reactive oxygen stress caused by mitochondria
uncoupling (36). Though there is some evidence of mitochondria
abnormalities in SOD1 transgenic mice (30,37), it however
Downloaded from https://academic.oup.com/hmg/advance-article-abstract/doi/10.1093/hmg/ddy260/5053938
by Cardiff University user
on 29 August 2018
8 Human Molecular Genetics, 2018, Vol. 00, No. 0
remains uncertain whether this is a driving mechanism behind
neurodegeneration rather than a secondary response to poor
health of the neuron. Interestingly, mitochondria damage in
ALS models may in part be due to altered levels of NAD+.
The protective activity of both WldS overexpression and Sarm1
deletion is likely dependent on maintaining neuronal levels
of NAD+. Fragmentation of mitochondria seen in cultured
motor neurons expressing mutant SOD1 can be rescued by
expression of the NAD+-dependent sirtuin SIRT3 (38), suggesting
that maintaining high levels of NAD+ may be beneficial to
neuronal survival in ALS. However, investigating the neuronal
contribution of NAD+ in vivo is compounded by its function
in maintaining normal glial activity. Depleted levels of NAD+
in cultured astrocytes drives oxidative stress in the cells,
subsequently contributing to their toxicity toward co-cultured
neurons, an effect that can be rescued by increasing levels of
astrocytic NAD+ (39). Further analysis of the role of NAD+ in
ALS and other neurodegenerative disease is required to increase
our understanding of how this molecule contributes to diverse
forms of axon destruction.
Indeed, the process by which motor axons degenerate in
ALS does not appear to be Wallerian-like; loss of distal motor
axons occurs prior to onset of symptoms in SOD1 transgenic
mouse models (40), progressing in a dying back pattern ulti-
mately leading to death of motor neuron cell bodies late in
disease (29). In contrast,Wallerian degeneration is characterized
by explosive, widespread fragmentation of the axon following
severing along its entire length. Interestingly, axonal injury has
previously been found to result in exacerbated degeneration
of motor neuron cell bodies in the spinal cords of SOD1G93A
transgenicmice (43,Neuroscience), suggesting the proximal por-
tion of damaged axons may contain a signaling cascade to
enhance destruction of the cell body. Notably, Sarm1 was found
to improve acute responses in amousemodel of traumatic brain
injury, where crush and shear injuries to axons are more typical
(41). We therefore speculate that multiple, potentially parallel
mechanisms for axon destruction exist: an acute pathway in
which Sarm1 (and an emerging cascade of downstream factors)
drives the destruction of severed axons and a second distinct
mechanism that occurs as axons undergoing chronic pathology
in neurodegenerative disease. This latter pathway may involve
Sarm1, but based on our data, we would predict in that case that
Sarm1 acts in a redundant fashion with other pathways that are
capable of executing axon degeneration even in the absence of
Sarm1. Future examination of additionalWallerian degeneration
molecules (e.g. Phr1 and Axundead) in thesemodels should clar-
ify this issue. Furthermore, it seems likely that selective protec-
tion of axons from degeneration without additionally impeding
the destruction of other cellular compartments like the soma
might be insufficient to entirely block neurodegeneration in ALS.
Notably inhibition of cell body death through deletion of the pro-
apoptotic gene Bax, though effective in rescuing cell body death,
did not to delay the progression of motor behavior functional
decline in SOD1 transgenic mice (30).
Further exploration of the Sarm1 signaling pathway in
neurodegeneration is warranted given the ability of Sarm1KO to
attenuate axon loss and improve behavioral outcomes inmodels
of Traumatic Brain Injury (TBI) (41) and peripheral neuropathy
(44). The role of Sarm1 in promoting axon degeneration
may indeed be context-dependent. That the nerve lesioning
experiments in our study found Sarm1 to drive axon destruction
in both young and aged axons suggests it may still be a
viable target for both juvenile (i.e. spinal muscular atrophy)
and age-associated neurodegenerative disease (i.e. Parkinson’s,
Alzheiemer’s, glaucoma). Until comprehensively tested in the
variety of models of neuronal injury and neurodegeneration
we will not know the full potential of Sarm1 and its associated
axon-destruction cascade as a therapeutic target.
Materials and Methods
Animals/scoring
High expression hSOD1G93A (B6.Cg-Tg(SOD1*G93A)1Gur/J) and
Sarm1 knockout (B6.129X1-Sarm1tm1Aidi/J) mice were acquired
from Jackson Labs and maintained on a C57Bl6/J backgrounds,
in a 12-hr light/dark cycle with ad libitum access to food and
water. Transgenic colonies were generated by breeding male
mice heterozygous for both Sarm1 and SOD1G93A transgene with
Sarm1 heterozygous or null females. Mice were scored daily
by researchers blinded to genotype for onset of trembling or
dragging/paralysis of one or more hind limbs. End-stage mice
unable to right within 30 s were euthanized. To encourage
feeding, animals approaching end stage had access to wet mash
food and gel water packs on their cage floor. For histological
experiments, littermate control mice not expressing the
SOD1G93A transgene older than p200 were used for comparison
to transgenic littermates. Experiments were approved by the
University ofMassachusettsMedical School Institutional Animal
Care and Use Committee.
Genotyping
All mice were genotyped using standard Polymerase Chain
Reaction (PCR) of DNA extracted from ear clippings. DNA was
extracted using the DNeasy Blood and Tissue Kit (Qiagen). The
following primers were used to amplify DNA for determining
genotype: human SOD1 transgene—fwd 5′CAT CAG CCC TAA
TCC ATC TGA 3′ and rev 5′TCT TAG AAA CCG CGA CTA ACA
ATC 3′; mouse endogenous SOD1—fwd 5′ GCA ATC CCA ATC
ACT CCA CAG 3 and rev 5′ GTC CAT GAG AAA CAA GAT GAC
3′ ; mouse endogenous Sarm1—fwd 5′ ACG CCT GGT TTC TTA
CTC TAC GA 3′ and rev 5′ GCT GGG GCC TCC TTA CCT CTT 3′;
and Sarm1 null neocassette—fwd 5′ CAG GTA GCC GGA TCA
AGC GTA TGC 3′ and rev 5′ CCT GTC CGG TGC CCT GAA TGA
ACT 3′ (Integrated DNA Technologies). Real-time quantitative
PCR was used to estimate human SOD1 transgene copy number.
Copy number estimation was calculated based on the difference
between the threshold cycles of the hSOD1 transgene compared
to an endogenous reference gene, ApoB. Mice with an estimated
copy number two standard deviations outside of the average
copy number for our colony were removed from the experiment.
Behavioral testing
Mice were tested weekly with an accelerating rotarod paradigm
starting at p50 on a five-station rotarod for mice (Med Associates
Inc.). At p50, mice were trained on the rotarod with 30 s at a
constant speed of 4 rpm and 30 s at an accelerating rate starting
at 4 rpm 1 day prior to the initial rotarod trial. The mice were
tested for 3 non-consecutive trials with the rotarod accelerating
from 4 rpm to 40 rpm for a maximum trial of 300 s. Symptomatic
mice that were unable to perform on the rotarod were scored
with a 0. Forelimb and all-limb grip strength was measured
weekly using a digital force gauge (Mark-10, USA). Each mouse
was tested five consecutive timeswith the highestmeasurement
recorded in newtons (N).
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MUNE
MUNE recordings were carried out as described previously
(27,42). Briefly, mice were anesthetized through inhalation of
isofluorane, maintained throughout the procedure via a nose
cone. A single hind limb was shaved, wiped with alcohol
and restrained on a Styrofoam board using adhesive tape.
A recording ring electrode (CareFusion) was coated with elec-
trode gel (SignaGel) and placed over the gastrocnemius muscle,
a reference electrode over the tendon and a grounding surface
electrode (CareFusion) on the tail. Disposable monopolar 28G
needle electrodes were used for stimulation. The stimulating
cathode was placed 5 mm proximal to the recording ring
electrode, with the anode placed subcutaneously at the midline
over the sacrum.
All electrophysiological recordings were made using a
portable electrodiagnostic system (Cardinal Synergy). For MUNE
and motor conduction studies the following settings were
used: low-pass filter, 30 Hz; high-pass filter, 10 kHz; and
Squarewave pulses of 0.1-ms duration. Supramaximal responses
were gradually generated (typically <10 mA). The distance
between distal and proximal stimulation sites was recorded.
The distal latency, distal and proximal CMAP amplitudes, distal
and proximal CMAP durations (measured from onset of initial
negative deflection to initial return to baseline), and conduction
velocity were determined for each nerve studied.
The low-pass filter was set at 20 Hz, and the high-pass filter
was set at 10 kHZ. Data were acquired with a sensitivity of
100 μV per division and sweep speed of 1ms per division.Using a
repetition rate of 1 per second, stimulus intensity was increased
and a singlemotor unit responsewas produced. Stimulationwas
further increased, and quantal increases in the response were
recorded. Individual motor unit amplitude of was calculated as
the mean of five quantal increases. MUNE was calculated from
the CMAP maximal amplitude divided by the mean amplitude
of surface-detected motor unit action potential. After recording
animals were euthanized by inhalation of isofluorane.
NMJ histology
Mice were euthanized via isofluorane inhalation and tran-
scardially perfused for 2 min with Phosphate-buffered saline
(PBS), followed by 5 min with 4% paraformaldehyde. The
gastrocnemius muscles were dissected and fixed overnight
in 1.5% paraformaldehyde and then transferred to a 25%
sucrose solution overnight (4◦C). After sinking, themuscles were
embedded in Optimal Cutting Temperature (OCT) compound
and 35 μm sections collected on a cryostat (Leica), frozen
on slides and stored at −80◦C. To stain for NMJs, slides
were thawed completely and allowed to dry before being
washed with PBS, followed by PBS with 0.4% triton-X100.
The muscle sections were blocked with 10% donkey serum
(EMD Millipore) in 0.4% triton-X100 PBS and then incubated
overnight with a 1:5 dilution of rabbit anti-synaptophysin
(Invitrogen) and a 1:1000 dilution of rabbit anti-neuronal class III
beta-tubulin (Covance) primary antibodies in blocking solution.
The sections were washed with PBS and then incubated
overnight with 1:500 donkey anti-rabbit secondary antibody
conjugated with alexa-488 (Life Technologies) and 1:500 alpha-
bungarotoxin conjugated with 555 nm fluorophore (Thermo
Fisher Scientific, USA) diluted in PBS. The sections were
washed with PBS and coverslips were mounted with Shandon
Immunomount (Fisher Scientific). NMJs were imaged on a Nikon
Eclipse Ti and scored for innervation status by two investigators
blinded to genotype.
Sciatic nerve axotomy
Assessment ofWallerian degeneration by lesioning of the sciatic
nerve was carried out as described previously (6). Briefly, mice
were anesthetized by inhalation of isofluorane, the skin was
shaved and cleaned with ethanol and povidone-iodine. A 5 mm
incisionwasmade to the skin and the sciatic nervewas exposed.
The sciatic nerve was grasped with fine forceps, and a 1–2 mm
portion of nerve was removed, ensuring that the distal portion
of nerve was lesioned completely. The incision was sutured, the
mouse was treated with appropriate analgesia and returned to
the home cage to recover. Mice were maintained for 14 days
post-axotomy, subsequently euthanized, and the sciatic nerve
was processed for semi-thin sectioning. The contralateral, intact
sciatic nerve was also dissected from each animal as an internal,
uninjured control.
Nerve semi-thin sectioning and toluidine blue histology
Sciatic nerves and L5 ventral nerve roots were dissected
from 4% paraformaldehyde perfusion fixed mice. Following
dissection nerves were immersion fixed overnight at 4◦C in 2.5%
gluteraldehyde in 0.1 M cacodylate buffer (pH 7.2). The following
day nerves were washed in cacodylate buffer and subsequently
post-fixed in 1% osmium tetroxide at room temperature for
1 hr. Following washing with dH2O, nerves were dehydrated
through a graded ethanol series of 0–100% in 20% increments,
followed by two changes of 100% ethanol. Nerves underwent
resin infiltration through two changes of 100% propylene
oxide followed by overnight incubation in a solution of 50%
SPI-Pon 812 resin in propylene oxide. Samples were then rinsed
with SPI-Pon 812 resin and polymerized in SPI-Pon 812 at 68◦C
in flat embedding molds. Semi-thin sections (0.6 μm) were
collected using an ultramicrotome (Reichert–Jung UltraCut E)
fitted with a diamond knife (Ultra 45o, DiATOME), mounted onto
glass slides and stained with 1% toluidine blue. Images were
captured using a 63× lens on a Nikon Ti-E inverted widefield
microscope and stitched using Velocity software (3i). Diameters
of regularly shaped healthy axons were measured using ImageJ
(National Institutes of Health). Images were thresholded and
particles of circularity 0.5–1 and minimum diameter 0.5 μm
were analyzed. Incorrectly identified objects were manually
removed from the data set. Minimum diameter was used for
statistical analysis. For total axons counts, healthy, irregularly
shaped axons not detected by particle analysis were manually
added to the data set.
Experimental design and statistical analysis
Experimental data were conducted by researchers blinded to the
genotype of animals.All statistical analyseswere conducted,and
graphs were plotted using Graphpad Prism (GraphPad Software,
Inc.). Unless stated otherwise, all charts show mean ± SEM.
Statistical test used are described in the relevant results or figure
legends.Tests used are unpaired t test, one-wayANOVAand two-
way ANOVA with Bonferroni post-hoc testing. P-values < 0.05
were considered significant for all statistical analyses used.
Supplementary Material
Supplementary Material is available at HMG online.
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